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Future Directions
Injection of Paroxetine and 17-DMAG Alters Reactive Oxygen 
Species Signaling in Coronary Arterioles from Aged Females
1Michaela Dukes, 1Amanda Jo LeBlanc, Ph.D., 1Evan P. Tracy, B.S., 
1Cardiovascular Innovation Institute, Department of Physiology, University of Louisville, Louisville, KY
• Elevated ROS levels block coronary microvessel b- adrenergic (bADR) function
and with the reduction of ROS through GRK2, the bADR function is restored. The
bADR function is not restored, however, by the HSP90 inhibition in aged female
rats. This study suggests microvessel bADR dysfunction may be linked to increased
oxidative stress. In order to design therapies to target coronary microvessel bADR
dysfuntion, comprehending the mechanisms behind the pathophysiology of
microvessel dysfunction including oxidative stress-linked bADR dysfunction is
critical.
Conclusions
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Introduction: In post-menopausal women, small coronary microvessel
dysfunction is the predominant heart disease presentation. There is currently no
single treatment to tackle the multifactorial etiology of microvessel dysfunction
including oxidative stress, hyperconstricted state, endothelial dysfunction, and
blunted beta-adrenergic function. In the heart, G protein-coupled receptors
(GPCRs), such as the b-adrenergic receptor (bADR), are active in mediating
vessel vasodilation to facilitate blood flow. The presence of GPCR kinase 2
(GRK2), which inhibit bADRs, increase in old age and may mediate blunted
capacity to vasodilate. Furthermore, GRK2 can be translocated to the
mitochondria via heat shock protein 90 (HSP90), where it is responsible for
accumulation of damaging reactive oxygen species (ROS). Increased ROS, in
turn, may also contribute to blunted bADR response via desensitization. Our
hypothesis is that coronary microvascular b-adrenergic desensitization in
old age is influenced in part by oxidative stress mediated by GRK2
translocation to the mitochondria via HSP90, reversible by 17-DMAG
(HSP90 inhibitor) or Paroxetine (GRK2 inhibitor) treatment.
Furthermore, b-adrenergic desensitization, we hypothesize, is inducible in
young age via exogenous ROS treatment. Methods: Female rat coronary
arterioles isolated from young (3 months) and old (24 months) were mounted in
a pressure myography system. Arterioles were infused with Mitosox
(superoxide) and 2,3-diaminonapthalene (nitric oxide) and the vessels were
incubated in 17-DMAG or Paroxetine for one hour. Changes in mean
fluorescence intensity (MFI) were monitored to compare concentration of ROS
within the arterioles. Old vessels were also subjected to bADR agonists
(dobutamine (b1), salbutamol (b2), BRL (b3), isoproterenol (b1 and b2), and
norepinephrine (b1 and a1/a2) in a dose response fashion in the presence or
absence of paroxetine or 17-DMAG. Dose responses were also evaluated in
young vessels with or without the presence of menadione (superoxide donor, 10
mM) and hydrogen peroxide (1 mM). Results: Paroxetine and 17-DMAG
significantly reduced superoxide levels in OC compared to YC vessels.
Paroxetine increases while 17-DMAG reduces NO density. Exogenous ROS
treatment of young vessel attenuated vasodilation response to all beta agonists.
For old vessels, the incubation in 17-DMAG did not restore vasodilation
capacity, whereas previously we have shown that paroxetine significantly
improves vasodilation response to norepinephrine. Conclusions: Coronary
microvessel bADR function is blunted by elevated ROS, and is restored upon
reduction of ROS through GRK2, but not HSP90 inhibition in the aged female
rat. The presented data suggests microvessel bADR dysfunction may be linked
to increased oxidative stress in age. Understanding mechanisms behind the
pathophysiology of microvessel dysfunction including oxidative stress-linked
bADR dysfunction is critical for designing therapies to target this disease.
Methods
• Advanced age is a significant risk factor for cardiovascular disease
and presents differently between sexes. In women of advanced age,
small coronary vessel disease is the predominant presentation of
cardiovascular disease.
• Currently, no one treatment is able to tackle the entirety of the
multi-factorial etiology of small artery dysfunction, including
increased oxidative stress, endothelial dysfunction, pathological
smooth muscle tone, and decreased bADR function and density.
• bADRs are vital in mediating vessel vasodilative capacity and
blood flow. GRKs, which accumulate in age, is a kinase that inhibit
bADRs and concomitantly increase
• We have previously shown that blockade of GRK2 with paroxetine
significantly increases vasodilation to norepinephrine
• Increases in MFI in response to 17-DMAG and paroxetine were observed with Mytopy1 (H2O2 dye) in the
YC, and decreases MFI in response to 17-DMAG and paroxetine were observed in the OC group (Figure
3a and b).• YC and YC-ROS results showed that the YC was able to vasodilate significantly more than the YC-ROS
group, which showed severe inhibiting effects on the arterioles’ ability to vasodilate (Figure 3c, d, g, and
h).• OC and OC+17-DMAG results of isoproterenol showed that the addition of the 17-DMAG decreased the
OC’s ability to vasodilate, which was opposite of what was predicted due to OC vessels tending to have
decreased ability to vasodilate already. (Figure 3e).• OC and OC +17-DMAG for Norepinephrine, Salbutamol, and BRL all showed an increased ability to
vasodilate the arterioles than the OC, though the margin of difference was not significant (Figure 3 e,i,
&j.)
Figure 1: Experimental setup. Rats
were sacrificed at 3 and 24 months for
YC and OC, respectively. a). Coronary
arterioles were dissected and
incorporated into a pressure myography
system and viewed under phase
contrast for dilation experiments or
fluorescence microscopy for ROS
signaling experiments. b). Intraluminal
pressure was held at 45 mmHg and
bath temperature was 37°C.
Figure 3: Injection of Paroxetine and 17-DMAG Alters Reactive Oxygen Species Signaling in Advanced Age. Vessels
from YC a), OC b), were infused with the H2O2 dye Mytpy1 and NO dye 2,3-diaminonapthalene (DAN), and incubated in
Paroxetine and 17-DMAG. There was an increase in percent relaxation in YC with each additional dose of isoproterenol,
salbutamol, and BRL, while YC-ROS showed minimal amounts of relaxation when added c), e), i). There was a slight decrease
with initial doses of norepinephrine due to earlier response to alpha blockers, which has been shown to vasoconstrict, rather
than dilate g). YC-ROS in the norepinephrine trial proved to continue to vasoconstrict after initial doses, indicating that beta
blocking did not occur g). All OC groups increased in percent relaxation less than the YC as expected and the incubation in 17-
DMAG did not show consistent evidence that it improved the vessels contractility e), f), i), j). Significant differences were
seen in MFI with addition of superoxide fluorescent marker Mitosox and Paroxetine as well as Mitosox and 17-DMAG with
YC having a large percent increase in MFI, while OC showing minimal negative change in MFI k.) * A two way ANOVA for
the MFI data was performed and a student's t test for dose responses with p < .05 being significant.
Results
Introduction
Abstract
• Improve the power of the experiments via additional n.
• Use confocal microscopy to quantify old vessel bADR density post incubation
with paroxetine/17-DMAG and young vessel with incubation with ROS.
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Figure 2: Protein 
Signaling Cascade 
Pathway. Pathway of the 
beta-adrenergic receptor 
(bADR) being signaled and 
the GPCRs and GRKs 
acting on the signal and 
moving to the 
mitochondria. Heat shock 
protein 90 (HSP90) 
mediated translocation of 
GRKs to the mitochondria 
increase the oxidative 
stress. Key: Green arrow 
indicates an activator, red 
indicates an 
inhibitor/scavenger. Light 
orange oval shapes indicate 
GRKs in the cell.
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